Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) today released a statement ahead of a bill markup in the U.S. House Committee on Ways & Means on the Prescription Drug Sunshine, Transparency, Accountability and Reporting (STAR) Act (H.R. 2113):

“The Prescription Drug STAR Act will help shine light on Big Pharma’s price-gouging and is a step in the right direction to achieve lower drug prices for patients,” said CSRxP executive director Lauren Aronson. “A key provision in the bill will require drug makers to submit to the Department of Health and Human Services a written justification of their prices for drugs with significantly high launch prices or excessive cost increases, holding drug makers accountable for their abusive price-gouging tactics.”

“While much more must be done, this bill marks positive progress toward providing relief for millions of patients who are struggling to afford their medications,” Aronson continued. “CSRxP applauds committee leaders for their commitment to leading on the issue of prescription drug prices and encourages all members of the committee to advance this market-based solution during the markup Tuesday.”